Premium
Dosing and Timing Effects of Anti‐CD40L Therapy
Author(s) -
GADKAR KAPIL G.,
SHODA LISL K. M.,
KREUWEL HUUB T. C.,
RAMANUJAN SAROJA,
ZHENG YANAN,
WHITING CHAN C.,
YOUNG DANIEL L.
Publication year - 2007
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1394.013
Subject(s) - pathogenesis , medicine , nod , dosing , diabetes mellitus , in silico , monoclonal antibody , bioinformatics , disease , type 2 diabetes , computational biology , immunology , pharmacology , antibody , biology , endocrinology , gene , genetics
: Several publications describing the use of anti‐CD40L monoclonal antibodies (anti‐CD40L) for the treatment of type 1 diabetes in non‐obese diabetic (NOD) mice have reported different treatment responses to similar protocols. The Entelos® Type 1 Diabetes PhysioLab® platform, a dynamic large‐scale mathematical model of the pathogenesis of type 1 diabetes, was used to study the effects of anti‐CD40L therapy in silico . An examination of the impact of pharmacokinetic variability and the heterogeneity of disease progression rate on therapeutic outcome provided insights that could reconcile the apparently conflicting data. Optimal treatment protocols were identified by exploring the dynamics of key pathophysiological pathways.